Biodegradable nanoparticles exposing a short anti-FLT1 peptide as antiangiogenic platform to complement docetaxel anticancer activity
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Materials Science and Engineering: C
- Vol. 102, 876-886
Abstract
No abstract availableKeywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG2014, 15764)
- Regione Campania (FESR 2014/2020, N. B61G18000470007)
This publication has 41 references indexed in Scilit:
- Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and ApoptosisACS Nano, 2013
- Antiangiogenic anticancer strategy based on nanoparticulate systemsExpert Opinion on Drug Delivery, 2011
- Nanotechnology-mediated targeting of tumor angiogenesisVascular Cell, 2011
- Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacyAdvanced Drug Delivery Reviews, 2009
- FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?Nature Reviews Cancer, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Polymeric nanoparticles for cancer therapyJournal of Drug Targeting, 2008
- Anti-Flt1 Peptide, a Vascular Endothelial Growth Factor Receptor 1–Specific Hexapeptide, Inhibits Tumor Growth and MetastasisClinical Cancer Research, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995